Juno Therapeutics

August 31, 2017
The CAR-T Revolution: Gilead’s $12B Acquisition of Kite Pharma & FDA Approval of Novartis’ Kymriah Signal Tipping Point for Promising Cancer Immunotherapies

The CAR-T Revolution: Gilead’s $12B Acquisition of Kite Pharma & FDA Approval of Novartis’ Kymriah Signal Tipping Point for Promising Cancer Immunotherapies

November 29, 2016

Promising Autologous CAR-T Cell Therapies Stumble: is this the End, or Just the Beginning?

September 14, 2016
A Brief Timeline of Cancer Immunotherapy

Cancer Immunotherapy: A Developmental Timeline & Examination of the Prior Art Paradox

July 1, 2015
Celgene & Juno Therapeutics announce landmark deal for CAR-T Cancer Therapies

Celgene & Juno Therapeutics announce landmark deal for CAR-T Cancer Therapies

Celgene and Juno Therapeutics have announced a decade long collaboration to advance potentially groundbreaking immunotherapies for patients with cancer and autoimmune diseases. The two companies will […]
Contact Us